Post AASLD Update in HCV Torino, 10 Gennaio Fattori che possono influenzare il trattamento: RVR e Lead in
|
|
- Clement Cox
- 8 years ago
- Views:
Transcription
1 Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze
2 Will predictors usefull with SOC continue to be usefull with PI Tx? Viral factors - HCV subtype - HCV RNA levels Host factors Unmodifiable - Race/ethnicity - Genetics - Age/advanced fibrosis SVR On treatment factors Duration of regimen Cumulative dose exposure Adherence RVR Host factors Modifiable Metabolic syndrome GT Iron overload
3 Open issues Is RVR important in triple therapy? Is IL28B essential in DAA treatment? Should we use the lead-in? And should we use it with both drugs? Is there need for precise staging of the disease? Is there difference between G1a and G1b?
4 Genotype 1 treatment naïve patients achieving RVR Peg+Rbv 20% SVR >90% Peg+Rbv+ BOC SVR >90% 44% Peg+Rbv + Telaprevir SVR >90% 58%.Jacobson IM, et al. N Engl J Med 2011;364:
5 SVR rates in patients eligible for shortened treatment duration Telaprevir Boceprevir Patients (%) Patients (%) n/n= 212/ /212 95/145 91/95 162/ /162 Naïves Relapsers* Early responders SVR in early responders Naïves Early responder: Telaprevir: undetectable HCV RNA at Weeks 4 and 12; BOC: undetectable HCV RNA at Weeks 8 24 *SVR rate from REALIZE with 48 weeks of overall treatment; retrospective analysis from the PROVE3 trial and Study 107 showed Adda SVRN, et al. CDDW/CASL 2012:A26 Telaprevir EU rates of % in prior relapsers with undetectable HCV RNA at Weeks 4 and 12 who received 24 weeks of overall treatment SmPC; Poordad F, et al. N Engl J Med 2011;364:
6 German Tubingen cohort: patients with undetectable HCV RNA (interim analysis) 100 Boceprevir based therapy (n=27) Patients (%) Wk 4 Wk 8 Wk 12 Wk 18 Wk 24 Per protocol ITT Berg C, et al. 2012
7 French ATUs: on-treatment efficacy results in F4 prior relapsers and partial responders (telaprevir) Telaprevir Boceprevir Patients with undetectable HCV RNA (%) 157/223 84/122 59/179 Week 4 Week 4 and 12 Week 8
8 RVR Conclusions RVR is important : - in naive pts to choose between triple therapy and SOC - to choose pts eligible for shortened treatment duration - to motivate patients to stay on therapy
9 Open issues Is RVR important in triple therapy? Is IL28B essential in DAA treatment? Should we use the lead-in? And should we use it with both drugs? Is there need for precise staging of the disease? Is there difference between G1a and G1b?
10 Predictors of SVR in previously non responders: RESPOND 2 study Baseline predictors Effect IL 28B rs genotype: CC vs TT Odds Ratio (95% CI) p value 2.0 ( ) 0.27 IL 28B rs genotype: CC vs CT 2.3 ( ) 0.06 IL 28B rs genotype: CT vs TT 0.86 ( ) 0.77 Baseline HCV RNA: 400,000 vs. >400,000 IU/mL 2.6 ( ) 0.12 Cirrhosis: no vs yes 2.0 ( ) 0.18 BMI: 30 vs. > ( ) 0.33 Genotype: 1b vs 1a/other/missing 1.1 ( ) 0.77 Race: non black vs black ( ) 0.68 Previous response: relapser vs nonresponder 2.6 ( ) Poordad F et al, Gastroenterology 2012
11 IL28B is no longer an important predictor of SVR when lead-in response is considered Baseline predictors Including TW4 response Odds Ratio Odds Ratio Effect p value p value (95% CI) (95% CI) IL 28B rs genotype: CC vs TT 2.0 ( ) ( ) 0.65 IL 28B rs genotype: CC vs CT 2.3 ( ) ( ) 0.13 IL 28B rs genotype: CT vs TT 0.86 ( ) ( ) 0.48 Baseline HCV RNA: 400,000 vs. >400,000 IU/mL 2.6 ( ) ( ) 0.20 Cirrhosis: no vs yes 2.0 ( ) ( ) 0.16 BMI: 30 vs. > ( ) ( ) 0.35 Genotype: 1b vs 1a/other/missing 1.1 ( ) ( ) 0.54 Race: non black vs black ( ) ( ) 0.71 Previous response: relapser vs nonresponder Log decline in HCV RNA at TW 4 ( 1 vs < 1 log 10 ) 2.6 ( ) ( ) ( ) 0.01 Poordad F et al, Gastroenterology 2012
12 IL28B vs RGT: detailed on-treatment monitoring provides similar information 49% Treatment duration: 24 wks 25% undetectable* Treatment duration: 48 or 72 wks 45% undetectable Baseline genotype distribution Overall Week 4 Weeks 8/12 Week 12 non-responders 16% 26% 4% 8% 14% 26% 26% 58% 44% 52% 60% 66% NR: non-responder; RGT: response-guided therapy *HCV RNA analyzed by PCR (LLOD 50 IU/mL) Mangia A, et al. Hepatology 2011;54:772 80
13 Open issues Is RVR important in triple therapy? Is IL28B essential in DAA treatment? Should we use the lead-in? And should we use it with both drugs? Is there need for precise staging of the disease? Is there difference between G1a and G1b?
14 Lead-in to sort-out pts less likely to respond with a protease inhibitor < 1 log decline 1 log decline SVR (%) SVR (%) REALIZE (TVR) [1] 0 RESPOND 2* (BOC) [2] 1. Foster G, et al. EASL Abstract Vierling JM, et al. EASL Abstract 481. *Pooled data from RGT and BOC/PR48.
15 REALIZE (telaprevir): SVR by Week 4 response according to prior response category (LI T12PR48 arm) <1 log 10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase Proportion of patients in each category with <1 log 10 HCV RNA reduction 10% 40% 59% 1 log 10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase 90% 94 60% 41% SVR (%) Prior relapsers Prior partial responders Prior null responders Prior relapsers Prior partial responders Prior null responders n/n= 8/13 10/18 6/41 106/113 16/27 15/28 SVR was defined as undetectable HCV RNA 24 weeks after last planned dose Foster GR, et al. J Hepatol 2011;54(Suppl. 1):S3
16 RESPOND-2: SVR by Week 4 Lead-in Response according to F3 and F4 score SVR% <1.0 log 10 decline F3/4 F3 F4 33 PR 0/3 0/0 0/3 BOCRGT 3/12 2/6 0/5 BOCPR48 2/16 1/5 1/11 SVR% >1.0 log 10 decline PR 2/11 2/5 0/6 BOCRGT 11/20 6/9 5/11 BOCPR48 20/23 4/5 16/ F3/4 F3 F4 89 Bruno S, et al. J Hepatol, IN PRESS
17 SPRINT-2/RESPOND-2: Separate Retrospective Subanalysis by IL28 Highest SVR rates in patients treated with boceprevir-based regimen who experienced a 1 log 10 decline in HCV RNA after 4-wk lead-in phase, regardless of IL28B genotype 100 PR48 BOC RGT BOC/PR SVR (%) n/n = 0 Wk 4 Response 0/ 2 2/ 3 < 1 log 50 2/ 4 56/ 75 83/ / / / / 45 37/ log < 1 log 1 log < 1 log CC CT TT 32 83/ / / / / / 26 23/ 28 1 log 26/ 34 Poordad F, et al. EASL Abstract 12.
18 Lead-in Conclusions 9-16% with < 1 log 10 decline in HCV RNA during lead-in can still become undetectable after 4 weeks of triple therapy, despite poor IFN responsiveness. Lead-in should not be used for futility as 33% with < 1 log 10 decline during lead-in achieve SVR Lead-in may be clinically usefull if physician is willing to take decision at week 4: SOC vs PI or stop therapy 100 ESTEBAN, EASL 2012 SVR (%) / 203/ 36/ 200/ 3/ 133/ n/n = BOC RGT BOC/PR48 PR48 Poordad F, et al. EASL Abstract 12. Poordad F, et al. N Engl J Med. 2011;364: < 1 log 10 decline in HCV RNA 1 log 10 decline in HCV RNA
19 Predictors of SVR in Poor IFN Responders (SPRINT 2 and RESPOND 2 studies combined) Pre treatment factors predictive of SVR Genotype 1b F0/1/2 BL viral load < IU/mL TW8 virologic response No patient with <3 log decline at TW8 achieved SVR Patients with undetectable HCV RNA at TW8 had best chance to achieve SVR Bacon B, Bruno S, et al., AASLD 2011
20 RESPOND 2: SVR in Early (Week 8 HCV RNA negative) and Late (Week 8 HCV RNA positive) Responders by Fibrosis Score SVR % /5951/59 24/4628/57 8/10 18/20 5/19 2/8 Early Responder Late Responder Early Responder F0/1/2 F3/4 BOC RGT BOC/PR48 Late Responder
21 Utility of Week 8 HCV RNA Testing in Experienced Patients Receiving Boceprevir Containing Regimens Week 12 Stopping Rule (n ¼ 670) Patients Stopped by Week 12 Rule (n) Additional Patients Stopped by Week 24 Rule (n) Total Patients Stopped (n) SVR Missed With Week 12 Rule (n) > 9.3 IU/mL (LLD) >25 IU/mL (LLQ) > 50 IU/mL (LLQ) > 100 IU/mL (LLQ) >1000 IU/mL (LLQ) <2-log decline from the baseline <3-log decline from the baseline Jacobson IM at al Hepatology 2012; 56:
22 TREATMENT-EXPERIENCED PATIENTS (PARTIAL AND NULL RESPONDERS), Metavir F0-F3 Lead in TW 4 HCV RNA 1 log decay < 1 log decay Add BOC or TVR ADD BOC or TVR BOC TVR BOC TVR TW 8 HCV RNA TW 12 HCV RNA ER LR 24 weeks 48 weeks <1000 UI/ml 24/48 weeks < 3 log decay STOP TREATMENT >1000 UI/ml STOP Bruno S and Mangia A DLD 2012 in press
23 Open issues Is RVR important in triple therapy? Is IL28B essential in DAA treatment? Should we use the lead-in? And should we use it with both drugs? Is there need for precise staging of the disease? Is there difference between G1a and G1b?
24 SVR rates by fibrosis stage in Boceprevir-treated patients
25 SVR rates by fibrosis stage in Telaprevir patients
26 Dosing Duration in All Patients with Compensated Cirrhosis TVR + Peg-IFN + RBV Peg-IFN + RBV >1000 IU/mL: Stop 3 drugs >1000 IU/mL: Stop 3 drugs Detectable: Stop PR Detectable: Stop PR Peg-IFN + RBV BOC+ Peg-IFN + RBV 100 IU/mL: Stop 3 drugs Detectable: Stop 3 drugs Telaprevir EU SmPC; Boceprevir EU SmPC
27 Open issues Is RVR important in triple therapy? Is IL28B essential in DAA treatment? Should we use the lead-in? And should we use it with both drugs? Is there need for precise staging of the disease? Is there difference between G1a and G1b?
28 Genotype 1b vs 1a Pts infected before 1955 are more often 1b 1 a was introduced later In more than 6000 Italian pts, the PROBE study showed that a better SVR was marginally associated with subtype 1 a (OR 1.4; 95% CI ) The AIFA study showed that naive pt 1 a infected had 6% higher SVR rates than 1b (37.1% vs 31.6%, p=<0.001).
29 SVR rate in treatment naive patients ADVANCE study SPRINT-2 study G1a G1b 0 G1a G1b PR-TVR PR PR-BOC PR Jacobson, NEJM 2011; Poordad NEJM 2011
30 Higher rates of viral break-through during Telaprevir / PEG / Riba Triple therapy for patients infected with G1a vs 1b Differences between subtypes? 100 NS3 protease sequence % HCV-1a HCV-1b 155 GIFRAAV GIFRAAV 40 HCV-1a AGG AAG (R155K) 20 8% HCV-1b CGG AAG (R155K) 0 11/12 GT 1a 1/12 GT 1b McHutchison et al., NEJM 2009 Sarrazin et al., Gastroenterology 2010
31 SVR rates (%) according to GENOTYPE, FIBROSIS STAGE and baseline VL in PATIENTS WITH POOR IFN RESPONSE (<1 log decline at TW4) COMBINED SPRINT 2 AND RESPOND 2 STUDIES Viral load Fibrosis G1a G1b HCV RNA (IU/ml) METAVIR % Patient number % Patient number F F > F F
32 Conclusions
33
34 IL28B vs RGT: detailed on-treatment monitoring provides similar information 49% Treatment duration: 24 wks 25% undetectable* Treatment duration: 48 or 72 wks 45% undetectable Baseline genotype distribution Overall Week 4 Weeks 8/12 Week 12 non-responders 16% 26% 4% 8% 14% 26% 26% 58% 44% 52% 60% 66% NR: non-responder; RGT: response-guided therapy *HCV RNA analyzed by PCR (LLOD 50 IU/mL) Mangia A, et al. Hepatology 2011;54:772 80
Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationVirological Monitoring of Hepatitis C Therapy
Virological Monitoring of Hepatitis C Therapy Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationPreamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
More informationDAA per l'epatite C: promesse e problemi. Giovanni Battista Gaeta Cattedra di Malattie Infettive UOC Epatiti Virali Seconda Università di Napoli
DAA per l'epatite C: promesse e problemi Giovanni Battista Gaeta Cattedra di Malattie Infettive UOC Epatiti Virali Seconda Università di Napoli SVR rates with telaprevir-based therapy versus PR alone in
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationNewton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
More informationVictrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD
Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationCurrent Antiviral Treatment of HCV cirrhosis
Current Antiviral Treatment of HCV cirrhosis Hugo R. Rosen, M.D. Waterman Endowed Chair in Liver Research Division Head, Gastroenterology & Hepatology Professor of Medicine and Immunology University of
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationProtease inhibitors based triple therapy in patients with advanced fibrosis/cirrhosis
Protease inhibitors based triple therapy in patients with advanced fibrosis/cirrhosis Michael P. Manns Department of Gastroenterology, Hepatology and Endocrinology White Nights of Hepatology, St. Petersburg,
More informationAASLD PRACTICE GUIDELINE
AASLD PRACTICE GUIDELINE An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases Marc G. Ghany, 1 David
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q1-2013 Conference Call - Presenting team Maris Hartmanis, CEO Charlotte
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationHow To Determine Sv
Clinical Nursing Experience with Direct Acting Antivirals (DAA s) Montreal Feb 24, 2012 Keri Earnshaw, RN, CCRP Jo-Ann Ford, RN, MSN BC Hepatitis Program Diamond Centre, VGH Disclosures K. Earnshaw Clinical
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationPatients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationManagement of HCV/HIV co-infection in the era of DAA-based therapy
Management of HCV/HIV co-infection in the era of DAA-based therapy Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany Conflict of interest I have received honoraria
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationMarc Ghany, MD, David R. Nelson, MD, Doris B. Strader, MD, David L. Thomas, MD, Leonard B. Seeff, MD
1 An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guidelines by the American Association for the Study of Liver Diseases Marc Ghany, MD, David R. Nelson, MD, Doris
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationBoceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford Brass, Antoine
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationPerspective Advances in the Treatment of Hepatitis C Virus Infection
Advances in HCV Treatment Volume 20 Issue 1 April/May 2012 Perspective Advances in the Treatment of Hepatitis C Virus Infection Since 2007, the annual age-adjusted mortality rate in hepatitis C virus (HCV)
More informationProtease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients?
Protease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients? Lindsey M. Childs, PharmD, MPH PGY2 Infectious Diseases Pharmacy Resident
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationDrug interactions in HCV: a case discussion
Drug interactions in HCV: a case discussion Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy antonio.craxi@unipa.it Disclosure of potential COIs (advisory boards, speakers bureau,
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationSCIENTIFIC DISCUSSION
London, 13 October 2005 Product name: PEGINTRON Procedure No. EMEA/H/C/280/II/54 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationREVIEW CLINICAL AND SYSTEMATIC REVIEWS
CLINICAL AND SYSTEMATIC S nature publishing group 1 Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center
More informationAcute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationIndividualizing treatment duration in hepatitis C virus genotype 2/3-infected patients
Liver International ISSN 1478-3223 REVIEW ARTICLE Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients Alessandra Mangia Liver Unit, IRCCS Hospital Casa Sollievo della
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationThe Use of Protease Inhibitors for the Treatment of Hepatitis C in Liver Transplant Recipients: Is a Bird in the Hand Worth Two in the Bush?
The Use of Protease Inhibitors for the Treatment of Hepatitis C in Liver Transplant Recipients: Is a Bird in the Hand Worth Two in the Bush? Christina Guerra, PharmD PGY-1 Pharmacy Resident University
More informationNEW APPROACHES TO THE MANAGEMENT OF HEPATITIS C IN HEMOPHILIA
TREATMENT OF HEMOPHILIA December 2012 No. 54 NEW APPROACHES TO THE MANAGEMENT OF HEPATITIS C IN HEMOPHILIA Fabien Zoulim François Bailly Hepatology Department Hospices Civils de Lyon, Université de Lyon
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationClinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
More informationCost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C Calogero Camma, 1 Salvatore Petta, 1 Marco Enea, 2 Raffaele Bruno, 3 Fabrizio Bronte, 1 Vincenza
More informationCommissioning Policy for Hepatitis C Treatments
Commissioning Policy for Hepatitis C Treatments Reference No: EMSCGP012V1 Version: 1 Ratified by: East Midlands Specialised Commissioning Group Date ratified: 05/06/09 Name of originator/author: Andrew
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationOver 185 million people are chronically
Hepatitis C Genotype 1 Virus With Low Viral Load and Rapid Virologic Response to Peginterferon/Ribavirin Obviates a Protease Inhibitor Brian L. Pearlman 1,2,3,4 and Carole Ehleben 2 The new standard of
More informationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Massachusetts Medical Society, April 2014 sponsored by Gilead Sciences 23.04.2014 Marie-Luise Lauterjung 1 Zweck der Studie
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationHEPATITIS C Treatment update 2012
HEPATITIS C Treatment update 2012 Fernando L. Merino, MD, FACP Assistant Professor Division of Infectious Diseases University of Kansas Medical Center None Disclosures HEPATITIS C Epidemiology Spectrum
More informationTreatment of Chronic Hepatitis C - September 2014 Update
Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationDaclatasvir for treating chronic hepatitis C
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care
More informationGuidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Drugs for Treatment
Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationNew Hepatitis C Wonder Drugs: Who Is Worth the Cost?
New Hepatitis C Wonder Drugs: Who Is Worth the Cost? Riddle me this, riddle me that, your HCV treatment, who will pay for that? Rachel Rogers, PharmD PGY2 Infectious Diseases Pharmacy Resident South Texas
More informationHEPATITIS C. Current approach and Therapeutic considerations
HEPATITIS C Current approach and Therapeutic considerations Disease Burden Approximately 3.2 million people in the U.S. infected (1.3%) with HCV Responsible for 16,000 death per year in the U.S. (CDC 2010)
More informationBack to main HCV Drug Development Section. December 2012. By Tracy Swan
Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to
More informationHepatitis C Antiviral Therapy
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Hepatitis C Antiviral Therapy Number 5.01.606 Effective Date
More informationHepatitis C Diagnose, Therapie und Verlaufskontrolle
Hepatitis C Diagnose, Therapie und Verlaufskontrolle Molekulare Diagnostik 2010 Weiter- und Fortbildungs-Sympsium 3.-4. März 2010 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB-Center University
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More information